References
- Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder. Data & Statistics in the United States. Available at: http://www.cdc.gov/ncbddd/adhd/data.html [Last accessed 20 June 2011]
- Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry 2010;19:325-40
- Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006;15:2119-38
- Biederman J, Faraone SV. Attention deficit hyperactivity disorder. Lancet 2005;366:237-48
- Danckaerts M, Sonuga-Barke EJS, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2010;19:83-105
- Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11
- Remschmidt H, Hoare P, Ettrich C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH: results of a 3-week, open-label study. Eur Child Adolesc Psychiatry 2005;14:297-304
- Niederkirchner K, Slawik L, Wermelskirchen D, et al. Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Rev Neurother 2011;11:499-508
- Mattejat F, Jungmann J, Meusers M, et al. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) – Eine Pilotstudie. Zeitschrift für Kinder- und Jugendpsychiatrie 1998;26:174-82
- Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998;59(Suppl 7):24-30
- Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999;46:857-70
- Conners CK, Sitarenios G, Parker JD, et al. The revised Conners’ parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-68
- Mattejat F, Remschmidt H. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) (The inventory of life quality in children and adolescents ILC). Bern: Verlag Hans Huber, 2006
- Mattejat F, Simon B, König U, et al. Lebensqualität bei psychisch kranken Kindern und Jugendlichen. Zeitschrift für Kinder- und Jugendpsychiatrie 2003;31:293-303
- Jozefiak T, Larsson B, Wichstrøm L, et al. Quality of Life as reported by school children and their parents: a cross-sectional survey. Health Qual Life Outcome 2008;6:34-45
- Shaffer D, Gould MS, Brasic J, et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31
- Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I93-101
- Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113(3 Pt 1):e206-16
- Sonuga-Barke EJ, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004;4:28